Robert M. Berman, MD
- 11Articles
- 32.1KReads
- 1999–2012Active
- 42Collaborators
- 65Citations
About
Robert M. Berman, MD, has published extensively on the clinical use of adjunctive aripiprazole in major depressive disorder, focusing on its effects on functional outcomes, sexual functioning, safety, and efficacy in various patient subgroups. His work also encompasses studies on schizophrenia and schizoaffective disorders, particularly regarding aripiprazole treatment in overweight patients. Additionally, Dr. Berman has contributed to research on antidepressant augmentation strategies and models of antidepressant action.
Publications
Improvement in Functional Outcomes With Adjunctive Aripiprazole Versus Placebo in Major Depressive Disorder: A Pooled Post Hoc Analysis of 3 Short-Term Studies
December 20, 2012
Beneficial Effects of Adjunctive Aripiprazole in Major Depressive Disorder Are Not Dependent on Antidepressant Therapy History: A Post Hoc Analysis of 3 Randomized, Double-Blind, Placebo-Controlled Trials
November 22, 2012
Effects of Adjunctive Aripiprazole on Sexual Functioning in Patients With Major Depressive Disorder and an Inadequate Response to Standard Antidepressant Monotherapy: A Post Hoc Analysis of 3 Randomized, Double-Blind, Placebo-Controlled Studies
January 13, 2011
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
